Breaking News

Cellvera Receives $20M Order for COVID Oral Antiviral Avigan

Favipiravir is a broad-spectrum oral antiviral drug that targets COVID-19 and 11 other infectious diseases.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cellvera, a global biopharmaceutical company developing and commercializing innovative antiviral therapies, and the Global Response Aid announced a supply of millions of its COVID-19 oral antiviral Avigan to Malaysia in the coming weeks. Cellvera holds directly, or through its affiliates worldwide (excluding Japan), exclusive rights to Avigan and all strengths and formulations of Favipiravir. This broad-spectrum oral antiviral drug targets COVID-19 and 11 other infectious diseases. Favipiravir w...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters